ATAI Investor Presentation Deck

CIAS & Schizophrenia landscape: RL-007's unique pharmacology, acute cognitive benefit and excellent tolerability differentiate it from the current standard of care available to CIAS & Schizophrenia patients Compound Development stage Mechanism of action Focused on treating cognitive impairment Potential for complimentary use with other therapies atai affiliate company Recognify RL-007 Phase 2 GABA/nicotinic modulator Boehringer Ingelheim BI-425809 Phase 2 GlyT1 inhibitor Biogen BIIB-104 Phase 2 AMPA agonist Key therapies in development for Schizophrenia Karuna Therapeutics KarXT Phase 3 Muscarinic M1/M4 receptor agonist Minerva Biosciences MT-210 Phase 3 5-HT2a/Sigma 2 receptor antagonist Sunovion SEP-363856 Phase 3 TAAR1 agonist Takeda 25 NBI-1065844 Phase 2 DAAO inhibitor

View entire presentation